Bullish & Foolish
Full INAB fundamentals All 466 on the Survival Watch

INABIN8BIO, INC.

Is IN8BIO struggling financially?

Yes, by its own account. IN8BIO told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

  • Reverse stock split

    The Company is headquartered in New York, New York. Reverse Stock Split On June 5, 2025, the Company effected a reverse stock split at a ratio of one-for-thirty (the "Reverse Stock Split").

    Form 10-Q, filed 7 May 2026. Read it on SEC.gov

  • Long-term agreements

    We have agreements with multiple GMP cell therapy laboratory facilities to manufacture product candidates for our Phase 1 and Phase 2/3 clinical trials. The multi-year agreements allow our medical technologists direct access to the facilities to assist and operate alongside the GMP facility staff.

    Form 10-K, filed 12 Mar 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$12.6M
Source filing
10-Q 7 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 7months

    If the burn speeds up

    Empty by Jan 2027

  • 10months

    If it eases off

    Empty by Apr 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$18.1M

÷

Cash burned over the last 12 months

$26.4M

What IN8BIO told the SEC

…expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern. The Company continues to maintain cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility. To continue to…

IN8BIO, INC., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 566.7% share-count increase The company issued stock. Each share now owns 85.0% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt